Sirion Biotech offers viral vector technologies for the efficient development and delivery of cell and gene therapies. Startup Headquartered in Martinsried, Germany, the company has a total of 50 employees at locations in Germany, France, and the USA. The company's solutions are used by various pharmaceutical and biotech companies, which are using them to research more than 25 different diseases.
With the acquisition of Sirion, Perkin Elmer aims to complement its Horizon Discovery portfolio, which includes gene editing and modulation tools for CRISPR, CRISPRi, and RNAi, custom cell lines for bioproduction, and base editing technologies. Furthermore, the acquisition is expected to further expand Perkin Elmer's existing cell and genetic research solutions with industry-leading high-content, in vivo, and cell painting screening technologies, innovative immunoassays, cell plate readers, and advanced automation, microfluidics, informatics, and analytics platforms. Christian Thirion, CEO of Sirion, explains:
"Our team is excited to collaborate with Perkin Elmer to further expand our leadership in viral vector technologies for cell and gene therapy. As part of Perkin Elmer, we will benefit from easier access to genome analysis, gene editing, and base editing technologies, as well as an excellent global infrastructure and presence."
Prahlad Singh, President and Chief Executive Officer of Perkin Elmer, added:
"Seventy percent of gene therapy trials today utilize viral vector approaches, and we expect this to continue in the future, given the high demand for targeted delivery of high payloads in the treatment of diseases such as cancer. By combining Sirion's innovative 'payload' delivery technology with our existing Horizon genetic material editing tools and phenotypic research solutions, we will be able to support the cell and gene therapy workflows of organizations seeking to streamline and accelerate their efforts."
Sirion Biotech showed great potential from the beginning
Marco Winzer, partner at HTGF, says:
"We are very proud to have supported Sirion's successful corporate development. As a seed investor, we are always looking for technologies that demonstrate great potential even before market entry, as well as highly motivated founders and teams. All of this was true at Sirion."
Roman Huber, Managing Director at Bayern Kapital, agrees:
"We were very impressed by Sirion's technical and market expertise from the very beginning and have actively supported the company. We are therefore very pleased with this tremendous success and wish Sirion all the best."
